H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $15

Futu News19:34 · Ratings

Emergent BioSolutions Receives $20 Million Contract to Supply Anthrax Vaccine to US Military

MT NewswiresJan 9 00:27

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

GlobeNewswireJan 8 20:45

Express News | Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense With Biothrax® (Anthrax Vaccine Adsorbed)

BreakingsJan 8 20:30

Vaccine Stocks Gain Amid Uptick in Flu, COVID-19, RSV

Seeking AlphaJan 6 22:47

Emergent BioSolutions (NYSE:EBS) Shareholder Returns Have Been Solid, Earning 285% in 1 Year

Simply Wall StDec 31, 2024 19:41